Sema Turker

Dr. Sema Turker

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2020 in European Journal of Cancer Care
Verified
Journal Article
Closed access
PDF file
AAAli Alkan
Ali Alkan
AYArzu Yaşar
Arzu Yaşar
ZGZeynep Gülsüm Güç
Zeynep Gülsüm Güç
MGMustafa Gürbüz
Mustafa Gürbüz
TBTuğba Başoğlu
Tuğba Başoğlu
FŞFiliz Çay Şenler
Filiz Çay Şenler

29 September 2019 in The Breast Journal
Verified
Journal Article
Closed access
PDF file
STSema Turker
Sema Turker
EÇEbru Çılbır
Ebru Çılbır
KYKerim Bora Yilmaz
Kerim Bora Yilmaz
EYEfe Yetişgin
Efe Yetişgin
GIGökşen İmAmoğlu
Gökşen İmAmoğlu
MAMustafa Altınbaş
Mustafa Altınbaş


18 September 2018 in Journal of Oncological Sciences
Verified
Journal Article
Open access
PDF file
STSema Turker
Sema Turker
HSHayriye Sahinli
Hayriye Sahinli
PPPerihan Perkin
Perihan Perkin
DYDogan Yazilitas
Dogan Yazilitas
NKNimet Oge Koklu
Nimet Oge Koklu
MAMustafa Altinbas
Mustafa Altinbas
We present a patient with uncommon metastases of lung cancer. The patient has been followed-up for early stage laryngeal carcinoma in the remission and has had dyspeptic complaints as well. A 62-year-old male patient had epigastric complaints for three months. In the upper endoscopy, a biopsy specimen taken from the polyp in the second region of the duodenum was reported as squamous cell cancer. Immunohistochemical staining of tumor cells were positive for CK5/6, p40, and p63. A mass in the right lung was detected on thorax tomography. The result of the transthoracic needle biopsy indicated squamous cell cancer. Duodenal metastasis of lung cancer is highly unlikely. Lesions below 1 cm can be safely removed endoscopically. Duodenal metastasis of primary lung cancer can be considered in the differential diagnosis of resistant dyspepsia.

20 September 2020 in Cureus
Verified
Journal Article
Open access
PDF file
CKCengiz Karacin
Cengiz Karacin
STSema Turker
Sema Turker
TETülay Eren
Tülay Eren
GİGökşen İnanç İmamoğlu
Gökşen İnanç İmamoğlu
KYKemalettin Yılmaz
Kemalettin Yılmaz
MAMustafa Altınbaş
Mustafa Altınbaş
Introduction Colonic wall thickening (CWT) is frequently observed incidentally via abdominal computerized tomography (aCT). Although the general approach to evaluating incidental CWT is a colonoscopic examination, there is a lack of definitive recommendation guidelines. Thus, we aimed to determine neoplasia rates and identify the factors predictive of neoplasia via colonoscopic examinations of patients with CWT incidentally diagnosed via aCT. Methods We retrospectively reviewed 5,300 colonoscopy reports. A total of 122 patients who had CWT incidentally observed via aCT were included in the study. CWT was graded as mild (3-5 mm), moderate (6-12 mm), or severe (>= 12 mm). A logistic regression model was used to determine the predictive factors for neoplasia. Results The mean age of the patients was 60 years, and abnormal findings were noted in 52% of the colonoscopies. Neoplastic lesions were detected in 24 patients (19.6%), while colon adenocarcinoma was detected in 8 patients (6.5%). Multivariate analysis showed that moderate-severe, focal, and asymmetric CWT were independent factors for predicting neoplasia (p=0.049, p=0.033, and p=0.018, respectively). Conclusion Pathological findings can be noted via colonoscopic examination in cases of incidental CWT; therefore, patients with moderate-severe, focal, or asymmetric CWT require colonoscopic examination for the purpose of detecting neoplasia.

18 April 2022 in Bosnian Journal of Basic Medical Sciences
Verified
Journal Article
Open access
PDF file
SESelin Akturk Esen
Selin Akturk Esen
YEYakup Ergun
Yakup Ergun
CECihan Erol
Cihan Erol
RARukiye Arikan
Rukiye Arikan
MEmuhammed muhiddin er
muhammed muhiddin er
DUDoğan Uncu
Doğan Uncu
Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of HER2-positive metastatic gastric adenocarcinoma. However, there is no comprehensive study on which platinum-based treatment should be preferred. This study aimed to compare the treatment response and survival characteristics of patients with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer who received fluorouracil, oxaliplatin, and leucovorin (mFOLFOX)+trastuzumab or cisplatin and fluorouracil (CF)+trastuzumab as first-line therapy. It was a multicenter, retrospective study of the Turkish Oncology Group, which included 243 patients from 21 oncology centers. There were 113 patients in the mFOLFOX+trastuzumab arm and 130 patients in the CF+trastuzumab arm. The median age was 62 years in the mFOLFOX+trastuzumab arm and 61 years in the CF+trastuzumab arm (P = 0.495). 81.4% of patients in the mFOLFOX+trastuzumab arm and 83.1% in the CF+trastuzumab arm had gastric tumor localization (P = 0.735). The median progression-free survival (PFS) was significantly higher in the mFOLFOX+trastuzumab arm (9.4 months vs. 7.3 months, P = 0.024). The median overall survival (OS) was similar in both groups (18.4 months vs. 15.1 months, P = 0.640). Maintenance trastuzumab was continued after chemotherapy in 101 patients. In this subgroup, the median OS was 23.3 months and the median PFS was 13.3 months. In conclusion, FOLFOX+trastuzumab is similar to CF+trastuzumab in terms of the median OS, but it is more effective in terms of the median PFS in the first-line treatment of HER2-positive metastatic gastric and GEJ cancer. The choice of treatment should be made by considering the prominent toxicity findings of the chemotherapy regimens.